On April 22, 2026, regulatory filings indicated that RA Capital Healthcare Fund LP, which is associated with RA Capital Management, L.P., sold 165,150 shares of Vor Biopharma Inc. (NASDAQ: VOR) common stock. The total value of these transactions reached approximately $2,604,415. According to the reported data, the shares were liquidated at a weighted average price of $15.77 per share, with individual transaction prices fluctuating between a low of $15.75 and a high of $15.85.
Following this divestment, RA Capital Healthcare Fund LP retains an indirect holding of 2,402,095 shares of Vor Biopharma common stock. The sale occurred during a window of notable price movement for the company; Vor Biopharma's stock has seen a decline of 16.76% over the previous week, settling at a closing price of $13.81. With a market capitalization currently estimated at $747.76 million, the biotech entity has been characterized by recent volatility. However, analysis from InvestingPro suggests that the stock is trading below its calculated Fair Value, which may imply potential upside for investors navigating the company's current trajectory.
Institutional Ownership and Governance
The relationship between RA Capital and Vor Biopharma is deeply integrated through ownership and governance. Both RA Capital Management, L.P. and RA Capital Healthcare Fund LP are identified as ten percent owners of the company. Furthermore, these entities hold representation on the Vor Biopharma board of directors. Specific reporting persons include Peter Kolchinsky and Rajeev Shah, who serve as managing members of the general partner of RA Capital Management, L.P. and are also listed as directors for Vor Biopharma. Dr. Andrew Levin, a Partner and Managing Director at RA Capital Management, L.P., also holds a seat on the Vor Biopharma board. While these individuals report certain interests, they disclaim beneficial ownership of the reported securities except regarding their specific pecuniary interests. The shares in question are held directly by the Fund.
Clinical Development and Strategic Pivot
Vor Biopharma is currently advancing its research and development pipeline, specifically focusing on a transition toward autoimmune disease treatments. A key milestone in this effort includes the commencement of dosing for the first patient in a global Phase 3 clinical trial targeting Sjögren’s disease. This trial utilizes the drug telitacicept and is expected to include roughly 250 adult participants to evaluate changes in disease activity over a 48-week period.
This strategic shift from oncology to autoimmune therapies has drawn attention from several analyst firms. Jefferies initiated coverage on the company with a buy rating and set a price target of $50, noting the importance of this clinical pivot. Stifel also maintained a buy rating, though it adjusted its price target to $40, citing Vor Biopharma's recent capital raise which exceeded $330 million. H.C. Wainwright similarly held a buy rating, despite slightly lowering its price target to $31. These institutional perspectives highlight the company's current financial position and its focused efforts on developing autoimmune therapies.